Evidence map›Paper›PMID 41144935›Full record

ArticleAdvanced healthcare materials2026

Plasma-Polymerized Nanoparticles Presenting Fibrillin-1 Drive Rapid Re-Endothelialization of Vascular Grafts.

Bob S L Lee, Yuen Ting Lam, Alex H P Chan, Praveesuda L Michael, Timothy C Mitchell, Jui Chien Hung, Miguel Santos, Khoon S Lim, Richard P Tan, Steven G Wise

Abstract read
In one paragraph

Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Bob S L LeeVictor Chang Cardiac Research Institute, Lowy Packer Building, Darlinghurst, NSW, 2010, Australia.
Yuen Ting LamSchool of Medical Sciences, Faculty of Health and Medicine, The University of Sydney, Camperdown, NSW, 2050, Australia.
Alex H P ChanSchool of Medical Sciences, Faculty of Health and Medicine, The University of Sydney, Camperdown, NSW, 2050, Australia.
Praveesuda L MichaelSchool of Medical Sciences, Faculty of Health and Medicine, The University of Sydney, Camperdown, NSW, 2050, Australia.
Timothy C MitchellSchool of Medical Sciences, Faculty of Health and Medicine, The University of Sydney, Camperdown, NSW, 2050, Australia.
Jui Chien HungSchool of Medical Sciences, Faculty of Health and Medicine, The University of Sydney, Camperdown, NSW, 2050, Australia.
Miguel SantosSchool of Medical Sciences, Faculty of Health and Medicine, The University of Sydney, Camperdown, NSW, 2050, Australia.
Khoon S LimSchool of Medical Sciences, Faculty of Health and Medicine, The University of Sydney, Camperdown, NSW, 2050, Australia.
Richard P TanSchool of Medical Sciences, Faculty of Health and Medicine, The University of Sydney, Camperdown, NSW, 2050, Australia.
Steven G WiseSchool of Medical Sciences, Faculty of Health and Medicine, The University of Sydney, Camperdown, NSW, 2050, Australia.ORCID 0000-0001-7964-819X

Funding

Australian Research Council FT230100249National Heart Foundation Future Leader Fellow 105622National Heart Foundation of Australia Postdoctoral Fellowship 106625National Heart Foundation Vanguard Grant 105875NSW Health in the form of NSW Cardiovascular Research Grants H20/28248NSW Health in the form of NSW Cardiovascular Research Grants H21/174585NSW Health in the form of NSW Cardiovascular Research Grants H22/98586NSW Ministry of Health
6 · The paper itself

Abstract

Small diameter vascular grafts made from expanded polytetrafluoroethylene (ePTFE) dominate clinical practice but are prone to high failure rates due to poor endothelialization, acute thrombosis or mid-term neointimal hyperplasia. The highly hydrophobic surface of ePTFE inhibits endothelial cell attachment and proliferation, making timely recovery of the protective endothelial layer a key challenge. Chemically inert, highly hydrophobic polymers such as ePTFE are amongst the most difficult to improve with biofunctionalization. To address this, a novel surface coating comprising a new class of plasma polymerized nanoparticles (PPN) functionalized with bioactive PF8, a recombinant fibrillin-1 peptide is developed. PPN surface modification significantly reduces ePTFE hydrophobicity, enabling efficient surface coating of PPN-PF8 and promoting endothelial attachment and proliferation in vitro. In a rat abdominal aortic interposition model, PPN-PF8 functionalized ePTFE grafts rapidly re-endothelialized, with extensive coverage of endothelial cells at 3 weeks post-implantation. This leads to increased tissue plasminogen activator (tPA) secretion and reduced fibrin deposition, indicating the formation of a healthy, functional endothelial layer. These findings highlight the potential of plasma-polymerized nanoparticles presenting fibrillin-1 to drive rapid re-endothelialization, offering an accessible and scalable method for improving the performance of small-diameter vascular grafts.

Indexed as

Blood Vessel ProsthesisFibrillin-1NanoparticlesAnimalsCell ProliferationEndothelial CellsHumansHuman Umbilical Vein Endothelial CellsMalePolytetrafluoroethyleneRatsRats, Sprague-DawleyFibrillin-1Polytetrafluoroethylenefibrillin‐1nanoparticlesplasma polymerizationre‐endothelialization

Identifiers

PMID41144935
PMCPMC12973347

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.